BR112022001657A2 - Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich - Google Patents
Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreichInfo
- Publication number
- BR112022001657A2 BR112022001657A2 BR112022001657A BR112022001657A BR112022001657A2 BR 112022001657 A2 BR112022001657 A2 BR 112022001657A2 BR 112022001657 A BR112022001657 A BR 112022001657A BR 112022001657 A BR112022001657 A BR 112022001657A BR 112022001657 A2 BR112022001657 A2 BR 112022001657A2
- Authority
- BR
- Brazil
- Prior art keywords
- ataxia
- friedreich
- treating
- fusion polypeptide
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
Abstract
polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich. um polipeptídeo de fusão tat-fxn útil no tratamento de indivíduos diagnosticados com ataxia de friedreich, cardiomiopatia hipertrófica ou ambos é descrito, assim como métodos de tratamento e composições farmacêuticas relacionados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962880073P | 2019-07-29 | 2019-07-29 | |
US201962891029P | 2019-08-23 | 2019-08-23 | |
PCT/US2020/044069 WO2021021931A1 (en) | 2019-07-29 | 2020-07-29 | Materials and methods for treating friedreich's ataxia |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022001657A2 true BR112022001657A2 (pt) | 2022-03-22 |
Family
ID=72087246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022001657A BR112022001657A2 (pt) | 2019-07-29 | 2020-07-29 | Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich |
Country Status (8)
Country | Link |
---|---|
US (2) | US11459363B2 (pt) |
EP (1) | EP4004022A1 (pt) |
CN (1) | CN114450309A (pt) |
AU (1) | AU2020321901A1 (pt) |
BR (1) | BR112022001657A2 (pt) |
CA (1) | CA3149188A1 (pt) |
IL (1) | IL290132A (pt) |
WO (1) | WO2021021931A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114902050A (zh) | 2019-11-25 | 2022-08-12 | 拉利玛生物医药公司 | 用于定量共济蛋白活性的方法 |
IL296805A (en) * | 2020-03-26 | 2022-11-01 | Larimar Therapeutics Inc | Molecules for transferring specific proteins to organelles |
WO2021222865A1 (en) | 2020-04-30 | 2021-11-04 | Larimar Therapeutics, Inc. | Methods for treating myelin associated diseases and mitochondria associated diseases |
WO2022126029A1 (en) * | 2020-12-12 | 2022-06-16 | Larimar Therapeutics, Inc. | Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof |
US20230357851A1 (en) | 2022-04-06 | 2023-11-09 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring frataxin-replacement therapy |
US20240142476A1 (en) | 2022-05-10 | 2024-05-02 | Larimar Therapeutics, Inc. | Frataxin-sensitive lipid markers for monitoring frataxin replacement therapy |
WO2023240201A1 (en) | 2022-06-08 | 2023-12-14 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2598525T3 (da) | 2010-07-28 | 2015-09-21 | Roberto Testi | Frataxin-mutanter |
US9260495B2 (en) * | 2011-06-17 | 2016-02-16 | Shire Human Genetic Therapies, Inc. | Mitochondrial targeting and therapeutic use thereof |
WO2013071440A1 (en) * | 2011-11-18 | 2013-05-23 | UNIVERSITé LAVAL | Methods and products for increasing frataxin levels and uses thereof |
US8912147B2 (en) * | 2013-04-15 | 2014-12-16 | BioBlast Pharma Ltd. | Mitochondrial proteins constructs and uses thereof |
WO2015183995A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof |
GB201414130D0 (en) * | 2014-08-08 | 2014-09-24 | Agency Science Tech & Res | Mutants of the bacteriophage lambda integrase |
US10617770B2 (en) | 2015-04-24 | 2020-04-14 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
KR20220015394A (ko) * | 2019-04-30 | 2022-02-08 | 라리마 테라퓨틱스, 인코포레이티드 | 프라탁신 대체 요법의 유효성 결정을 위한 프라탁신 민감성 마커 |
WO2021011929A1 (en) * | 2019-07-18 | 2021-01-21 | Chondrial Therapeutics, Inc. | Use of frataxin for treating leigh syndrome, french canadian type |
IL296805A (en) * | 2020-03-26 | 2022-11-01 | Larimar Therapeutics Inc | Molecules for transferring specific proteins to organelles |
WO2021222865A1 (en) * | 2020-04-30 | 2021-11-04 | Larimar Therapeutics, Inc. | Methods for treating myelin associated diseases and mitochondria associated diseases |
-
2020
- 2020-07-29 EP EP20757116.7A patent/EP4004022A1/en active Pending
- 2020-07-29 WO PCT/US2020/044069 patent/WO2021021931A1/en unknown
- 2020-07-29 AU AU2020321901A patent/AU2020321901A1/en active Pending
- 2020-07-29 US US16/942,276 patent/US11459363B2/en active Active
- 2020-07-29 BR BR112022001657A patent/BR112022001657A2/pt unknown
- 2020-07-29 CN CN202080068105.4A patent/CN114450309A/zh active Pending
- 2020-07-29 CA CA3149188A patent/CA3149188A1/en active Pending
-
2022
- 2022-01-26 IL IL290132A patent/IL290132A/en unknown
- 2022-08-31 US US17/900,450 patent/US20230242600A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3149188A1 (en) | 2021-02-04 |
WO2021021931A1 (en) | 2021-02-04 |
US20230242600A1 (en) | 2023-08-03 |
US20210047378A1 (en) | 2021-02-18 |
US11459363B2 (en) | 2022-10-04 |
CN114450309A (zh) | 2022-05-06 |
EP4004022A1 (en) | 2022-06-01 |
IL290132A (en) | 2022-03-01 |
AU2020321901A1 (en) | 2022-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022001657A2 (pt) | Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich | |
Vaubourgeix et al. | Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells | |
Choy et al. | The multifunctional LigB adhesin binds homeostatic proteins with potential roles in cutaneous infection by pathogenic Leptospira interrogans | |
BR112015006828A8 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 | |
Carpenter et al. | A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801 | |
BR112021022874A2 (pt) | Proteínas de ligação epcam e métodos de uso | |
BRPI0921999B8 (pt) | uso de uma quantidade terapeuticamente eficaz de células tronco placentárias | |
BR112017018728A2 (pt) | sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada | |
BRPI0608249A2 (pt) | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
BR112021021047A2 (pt) | Métodos e composições para modulação de emenda e tradução | |
De Ridder et al. | Muscular dystrophy with arrhythmia caused by loss-of-function mutations in BVES | |
BR112022001359A2 (pt) | Método e composição para anticorpos anti-cd73 e variantes | |
BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
BR112021026789A2 (pt) | Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas | |
BR112017022779A2 (pt) | métodos para detectar uma mutação de deleção em marco (indel) no éxon 9 do gene da calreticulina, para diagnosticar uma doença hematopoiética em um paciente, para determinar a probabilidade de um paciente desenvolver uma mutação em um gene de via jak-stat para determinar o prognóstico de um paciente com uma doença mieloproliferativa, kit, e, sonda ou iniciador oligonucleotídico | |
BR112021021224A2 (pt) | Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo | |
BR112022011975A2 (pt) | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo | |
BR122018077204B8 (pt) | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica | |
Kim et al. | Identification of a novel angiogenic peptide from periostin | |
BR0303912A (pt) | Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável | |
BR112017019431A2 (pt) | material de implante de compósito | |
BR112016030507A8 (pt) | compostos relacionados à vitamina d, composição farmacêutica, e kit | |
BR112021019032A2 (pt) | Vetores de fator h e usos dos mesmos |